Cargando…
New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol
INTRODUCTION: With the pressing need to develop treatments that slow or stop the progression of Alzheimer’s disease, new tools are needed to reduce clinical trial duration and validate new targets for human therapeutics. Such tools could be derived from neurophysiological measurements of disease. ME...
Autores principales: | Lanskey, Juliette Helene, Kocagoncu, Ece, Quinn, Andrew J, Cheng, Yun-Ju, Karadag, Melek, Pitt, Jemma, Lowe, Stephen, Perkinton, Michael, Raymont, Vanessa, Singh, Krish D, Woolrich, Mark, Nobre, Anna C, Henson, Richard N, Rowe, James B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756184/ https://www.ncbi.nlm.nih.gov/pubmed/36521898 http://dx.doi.org/10.1136/bmjopen-2021-055135 |
Ejemplares similares
-
Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics
por: Kocagoncu, Ece, et al.
Publicado: (2020) -
Neurophysiological and Brain Structural Markers of Cognitive Frailty Differ from Alzheimer's Disease
por: Kocagoncu, Ece, et al.
Publicado: (2022) -
Linking dopamine neurotransmission and neurogenesis: The evolutionary history of the NTAD (NCAM1-TTC12-ANKK1-DRD2) gene cluster
por: Mota, Nina Roth, et al.
Publicado: (2012) -
Bilingualism: A Global Public Health Strategy for Healthy Cognitive Aging
por: Mendis, Sahan Benedict, et al.
Publicado: (2021) -
Evidence and implications of abnormal predictive coding in dementia
por: Kocagoncu, Ece, et al.
Publicado: (2021)